Influence of microbiota on intestinal immune system in Ulcerative colitis and its intervention

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Zhang, Sai Long ^a   Wang, Shu Na ^a   Miao, Chao Yu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial cells; Host immune response; Intestinal microbiota; Therapeutic targets; Ulcerative colitis

Indexed keywords

EXOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; NOD LIKE PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDETES; BIFIDOBACTERIUM; CANDIDA ALBICANS; CARDIOVASCULAR DISEASE; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE INFECTION; CYTOKINE RELEASE; ESCHERICHIA COLI; EUBACTERIUM RECTALE; FAECALIBACTERIUM PRAUSNITZII; FUSOBACTERIUM VARIUM; HELICOBACTER PYLORI; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; MOLECULARLY TARGETED THERAPY; PEPTOCLOSTRIDIUM DIFFICILE; REGULATORY T LYMPHOCYTE; REVIEW; ULCERATIVE COLITIS;

EID: 85035320218     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01674     Document Type: Review

References (165)

1. Head KA, Jurenka JS. Inflammatory bowel disease part 1: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev (2003) 8:247-83
2. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ (2013) 346:f432. doi:10.1136/bmj.f432
3. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet (2017) 389:1756-70. doi:10.1016/s0140-6736(16)32126-2
4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, ChernoffG, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2012) 142:46-54.e42; quiz e30. doi:10.1053/j.gastro.2011.10.001
5. de Souza HSP. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol (2017) 33:222-9. doi:10.1097/mog.0000000000000364
6. Marchesi J, Shanahan F. The normal intestinal microbiota. Curr Opin Infect Dis (2007) 20:508-13. doi:10.1097/QCO.0b013e3282a56a99
7. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science (2012) 336:1268-73. doi:10.1126/science.1223490
8. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature (2009) 457:480-4. doi:10.1038/nature07540
9. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science (2013) 341:1237439. doi:10.1126/science.1237439
10. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology (2008) 134:577-94. doi:10.1053/j.gastro.2007.11.059
11. Johansson MEV, Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A (2011) 108:4659-65. doi:10.1073/pnas.1006451107
12. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol (2013) 29:85-91. doi:10.1097/MOG.0b013e32835a670e
13. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol (2013) 29:49-54. doi:10.1097/MOG.0b013e32835a3493
14. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science (2011) 334:255-8. doi:10.1126/science.1209791
15. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol (2016) 14:e1002533. doi:10.1371/journal.pbio.1002533
16. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 104:13780-5. doi:10.1073/pnas.0706625104
17. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature (2011) 473:174-80. doi:10.1038/nature09944
18. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature (2012) 486:207-14. doi:10.1038/nature11234
19. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science (2005) 308:1635-8. doi:10.1126/science.1110591
20. Hold GL, Schwiertz A, Aminov RI, Blaut M, Flint HJ. Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl Environ Microbiol (2003) 69:4320-4. doi:10.1128/AEM.69.7.4320-4324.2003
21. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Kohler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr (2010) 157:240-4.e1. doi:10.1016/j.jpeds.2010.02.046
22. Suau A, Rochet V, Sghir A, Gramet G, Brewaeys S, Sutren M, et al. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol (2001) 24:139-45. doi:10.1078/0723-2020-00015
23. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2011) 5:220-30. doi:10.1038/ismej.2010.118
24. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol (2000) 66:1654-61. doi:10.1128/AEM.66.4.1654-1661.2000
25. Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol (2002) 52:2141-6. doi:10.1099/00207713-52-6-2141
26. Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol (2014) 20:15657-63. doi:10.3748/wjg.v20.i42.15657
27. Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis (2013) 7:e558-68. doi:10.1016/j.crohns.2013.04.002
28. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 105:16731-6. doi:10.1073/pnas.0804812105
29. Sarrabayrouse G, Bossard C, Chauvin JM, Jarry A, Meurette G, Quevrain E, et al. CD4CD8alphaalpha lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol (2014) 12:e1001833. doi:10.1371/journal.pbio.1001833
30. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis (2009) 15:1183-9. doi:10.1002/ibd.20903
31. Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut (2017) 66:863-71. doi:10.1136/gutjnl-2015-309940
32. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J (2017) 11:841-52. doi:10.1038/ismej.2016.176
33. Knoll RL, Forslund K, Kultima JR, Meyer CU, Kullmer U, Sunagawa S, et al. Gut microbiota differs between children with inflammatory bowel disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. Am J Physiol Gastrointest Liver Physiol (2017) 312:G327-39. doi:10.1152/ajpgi.00293.2016
34. Prosberg M, Bendtsen F, Vind I, Petersen AM, Gluud LL. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scand J Gastroenterol (2016) 51:1407-15. doi:10.1080/00365521.2016.1216587
35. Li KY, Wang JL, Wei JP, Gao SY, Zhang YY, Wang LT, et al. Fecal microbiota in pouchitis and ulcerative colitis. World J Gastroenterol (2016) 22:8929-39. doi:10.3748/wjg.v22.i40.8929
36. Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung KA, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis (2016) 10:943-52. doi:10.1093/ecco-jcc/jjw051
37. Lopez-Siles M, Martinez-Medina M, Suris-Valls R, Aldeguer X, Sabat-Mir M, Duncan SH, et al. Changes in the abundance of Faecalibacterium prausnitzii phylogroups I and II in the intestinal mucosa of inflammatory bowel disease and patients with colorectal cancer. Inflamm Bowel Dis (2016) 22:28-41. doi:10.1097/mib.0000000000000590
38. Yao P, Cui M, Wang H, Gao H, Wang L, Yang T, et al. Quantitative analysis of intestinal flora of Uygur and Han ethnic Chinese patients with ulcerative colitis. Gastroenterol Res Pract (2016) 2016:9186232. doi:10.1155/2016/9186232
39. Lopez-Siles M, Martinez-Medina M, Abella C, Busquets D, Sabat-Mir M, Duncan SH, et al. Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. Appl Environ Microbiol (2015) 81:7582-92. doi:10.1128/aem.02006-15
40. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol (2014) 52:398-406. doi:10.1128/jcm.01500-13
41. Lopez-Siles M, Martinez-Medina M, Busquets D, Sabat-Mir M, Duncan SH, Flint HJ, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int J Med Microbiol (2014) 304:464-75. doi:10.1016/j.ijmm.2014.02.009
42. Varela E, Manichanh C, Gallart M, Torrejon A, Borruel N, Casellas F, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther (2013) 38:151-61. doi:10.1111/apt.12365
43. Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol (2013) 13:20. doi:10.1186/1471-230x-13-20
44. Vermeiren J, Van den Abbeele P, Laukens D, Vigsnaes LK, De Vos M, Boon N, et al. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol (2012) 79:685-96. doi:10.1111/j.1574-6941.2011.01252.x
45. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett (2009) 294:1-8. doi:10.1111/j.1574-6968.2009.01514.x
46. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut (2014) 63:1275-83. doi:10.7150/ijms.6934
47. Martín R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis (2014) 20:417-30. doi:10.1097/01.mib.0000440815.76627.64
48. Martín R, Miquel S, Chain F, Natividad JM, Jury J, Lu J, et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol (2015) 15:67. doi:10.1186/s12866-015-0400-1
49. Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One (2014) 9:e109146. doi:10.1371/journal.pone.0109146
50. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev (2009) (4):CD006289. doi:10.1002/14651858.CD006289.pub2
51. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 6:53-68. doi:10.1177/1756283x12454590
52. Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 16:4892-904. doi:10.3748/wjg.v16.i39.4892
53. Young VB, Hanna PC. Overlapping roles for toxins in Clostridium difficile infection. J Infect Dis (2014) 209:9-11. doi:10.1136/gutjnl-2013-304833
54. Mabardy A, McCarty J, Hackford A, Dao H. IBD: a growing and vulnerable cohort of hospitalized patients with Clostridium difficile infection. Am Surg (2017) 83:605-9
55. Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology (2017) 153:430-8.e2. doi:10.1053/j.gastro.2017.04.044
56. Tang YM, Stone CD. Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment. Clin J Gastroenterol (2017) 10:112-23. doi:10.1007/s12328-017-0719-2
57. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 5:339-44. doi:10.1016/j.cgh.2006.12.027
58. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol (2010) 4:589-600. doi:10.1586/egh.10.55
59. Dieterle MG, Young VB. Reducing recurrence of C. difficile infection. Cell (2017) 169:375. doi:10.1016/j.cell.2017.03.039
60. Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med (2015) 66:373-86. doi:10.1146/annurev-med-070813-114317
61. Gong J, Si W, Forster RJ, Huang R, Yu H, Yin Y, et al. 16S rRNA gene-based analysis of mucosa-associated bacterial community and phylogeny in the chicken gastrointestinal tracts: from crops to ceca. FEMS Microbiol Ecol (2007) 59:147-57. doi:10.1111/j.1574-6941.2006.00193.x
62. Li YN, Huang F, Cheng HJ, Li SY, Liu L, Wang LY. Intestine-derived Clostridium leptum induces murine tolerogenic dendritic cells and regulatory T cells in vitro. Hum Immunol (2014) 75:1232-8. doi:10.1016/j.humimm.2014.09.017
63. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev (2007) 20:593-621. doi:10.1128/CMR.00008-07
64. Xu J, Mahowald MA, Ley RE, Lozupone CA, Hamady M, Martens EC, et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol (2007) 5:e156. doi:10.1371/journal.pbio.0050156
65. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell (2005) 122:107-18. doi:10.1016/j.cell.2005.05.007
66. Chiu CC, Ching YH, Wang YC, Liu JY, Li YP, Huang YT, et al. Monocolonization of germ-free mice with Bacteroides fragilis protects against dextran sulfate sodium-induced acute colitis. Biomed Res Int (2014) 2014:675786. doi:10.1155/2014/675786
67. Lopetuso LR, Petito V, Graziani C, Schiavoni E, Paroni Sterbini F, Poscia A, et al. Gut microbiota in health, diverticular disease, irritable bowel syndrome, and inflammatory bowel diseases: time for microbial marker of gastrointestinal disorders? Dig Dis (2017) 36:56-65. doi:10.1159/000477205
68. Zitomersky NL, Atkinson BJ, Franklin SW, Mitchell PD, Snapper SB, Comstock LE, et al. Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS One (2013) 8:e63686. doi:10.1371/journal.pone.0063686
69. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature (2008) 453:620-5. doi:10.1038/nature07008
70. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A (2010) 107:12204-9. doi:10.1073/pnas.0909122107
71. Im E, Jung J, Pothoulakis C, Rhee SH. Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) mice. Gastroenterology (2014) 147:667-79.e10. doi:10.1053/j.gastro.2014.05.034
72. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 98:694-702. doi:10.1016/0016-5085(90)90290-H
73. Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N, et al. Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc Natl Acad Sci U S A (2004) 101:14919-24. doi:10.1073/pnas.0404172101
74. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut (2006) 55:1760-7. doi:10.1136/gut.2005.078824
75. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect (2003) 5:115-22. doi:10.1016/S1286-4579(02)00080-1
76. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol (2000) 15:61-8. doi:10.1046/j.1440-1746.2000.02045.x
77. Bamba T, Matsuda H, Endo M, Fujiyama Y. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol (1995) 30(Suppl 8):45-7
78. Hansen JJ, Huang Y, Peterson DA, Goeser L, Fan TJ, Chang EB, et al. The colitis-associated transcriptional profile of commensal Bacteroides thetaiotaomicron enhances adaptive immune responses to a bacterial antigen. PLoS One (2012) 7:e42645. doi:10.1371/journal.pone.0042645
79. Hudcovic T, Kozakova H, Kolinska J, Stepankova R, Hrncir T, Tlaskalova-Hogenova H. Monocolonization with Bacteroides ovatus protects immunodeficient SCID mice from mortality in chronic intestinal inflammation caused by long-lasting dextran sodium sulfate treatment. Physiol Res (2009) 58:101-10
80. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One (2009) 4:e6026. doi:10.1371/journal.pone.0006026
81. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ (2003) 81:197-204
82. Solo-Gabriele HM, Wolfert MA, Desmarais TR, Palmer CJ. Sources of Escherichia coli in a coastal subtropical environment. Appl Environ Microbiol (2000) 66:230-7. doi:10.1128/AEM.66.1.230-237.2000
83. Power ML, Littlefield-Wyer J, Gordon DM, Veal DA, Slade MB. Phenotypic and genotypic characterization of encapsulated Escherichia coli isolated from blooms in two Australian lakes. Environ Microbiol (2005) 7:631-40. doi:10.1111/j.1462-2920.2005.00729.x
84. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe (2007) 2:119-29. doi:10.1016/j.chom.2007.06.010
85. Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol (2015) 110:921-30. doi:10.1038/ajg.2015.149
86. Nagao-Kitamoto H, Shreiner AB, Gillilland MG III, Kitamoto S, Ishii C, Hirayama A, et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell Mol Gastroenterol Hepatol (2016) 2:468-81. doi:10.1016/j.jcmgh.2016.02.003
87. Pilarczyk-Zurek M, Chmielarczyk A, Gosiewski T, Tomusiak A, Adamski P, Zwolinska-Wcislo M, et al. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol (2013) 13:61. doi:10.1186/1471-230X-13-61
88. Sha S, Xu B, Wang X, Zhang Y, Wang H, Kong X, et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis (2013) 75:245-51. doi:10.1016/j.diagmicrobio.2012.11.022
89. Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol (2010) 59:1114-22. doi:10.1099/jmm.0.021170-0
90. Siczek K, Zatorski H, Chmielowiec-Korzeniowska A, Pulit-Prociak J, Smiech M, Kordek R, et al. Synthesis and evaluation of anti-inflammatory properties of silver nanoparticle suspensions in experimental colitis in mice. Chem Biol Drug Des (2017) 89:538-47. doi:10.1111/cbdd.12876
91. Martinez-Medina M, Aldeguer X, Lopez-Siles M, Gonzalez-Huix F, Lopez-Oliu C, Dahbi G, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis (2009) 15:872-82. doi:10.1002/ibd.20860
92. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 127:80-93. doi:10.1053/j.gastro.2004.03.054
93. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, BrostoffJ. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis (2005) 11:481-7. doi:10.1097/01.MIB.0000159663.62651.4f
94. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 127:412-21. doi:10.1053/j.gastro.2004.04.061
95. Sokol H, Lepage P, Seksik P, Dore J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol (2006) 44:3172-7. doi:10.1128/JCM.02600-05
96. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 140:1720-8. doi:10.1053/j.gastro.2011.01.054
97. Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol (2014) 5:213-27. doi:10.4291/wjgp.v5.i3.213
98. Low D, Tran HT, Lee IA, Dreux N, Kamba A, Reinecker HC, et al. Chitin-binding domains of Escherichia coli ChiA mediate interactions with intestinal epithelial cells in mice with colitis. Gastroenterology (2013) 145:602-12.e9. doi:10.1053/j.gastro.2013.05.017
99. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 13:R79. doi:10.1186/gb-2012-13-9-r79
100. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 126:1620-33. doi:10.1053/j.gastro.2004.03.024
101. Imaoka A, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, et al. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol (2008) 14:2511-6. doi:10.3748/wjg.14.2511
102. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog (2012) 8:e1002714. doi:10.1371/journal.ppat.1002714
103. Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther (2013) 38:329-42. doi:10.3748/wjg.v19.i22.3404
104. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol (2012) 47:609-18. doi:10.1007/s00535-012-0592-1
105. Keenan JI, Beaugie CR, Jasmann B, Potter HC, Collett JA, Frizelle FA. Helicobacter species in the human colon. Colorectal Dis (2010) 12:48-53. doi:10.1111/j.1463-1318.2008.01672.x
106. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology (1994) 107:1671-4. doi:10.1016/0016-5085(94)90806-0
107. Kabir S. Detection of Helicobacter pylori DNA in feces and saliva by polymerase chain reaction: a review. Helicobacter (2004) 9:115-23. doi:10.1111/j.1083-4389.2004.00207.x
108. Kabir S. Detection of Helicobacter pylori in faeces by culture, PCR and enzyme immunoassay. J Med Microbiol (2001) 50:1021-9. doi:10.1099/0022-1317-50-12-1021
109. Engler DB, Leonardi I, Hartung ML, Kyburz A, Spath S, Becher B, et al. Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis (2015) 21(4):854-61. doi:10.1097/MIB.0000000000000318
110. Liu JY, Li YP, Huang YT, Chuang HL, Papamichael K, Konstantopoulos P, et al. Helicobacter pylori infection and inflammatory bowel disease: is there a link? Biomed Res Int (2014) 20:6374-85
111. Yu Q, Zhang S, Li L, Xiong L, Chao K, Zhong B, et al. Enterohepatic Helicobacter species as a potential causative factor in inflammatory bowel disease: a meta-analysis. Medicine (Baltimore) (2015) 94:e1773. doi:10.1097/md.0000000000001773
112. Ohkusa T, Yoshida T, Sato N, Watanabe S, Tajiri H, Okayasu I. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol (2009) 58:535-45. doi:10.1099/jmm.0.005801-0
113. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol (2002) 17:849-53. doi:10.1046/j.1440-1746.2002.02834.x
114. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis (2011) 17:1971-8. doi:10.1002/ibd.21606
115. Tahara T, Shibata T, Kawamura T, Okubo M, Ichikawa Y, Sumi K, et al. Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. Dig Dis Sci (2015) 60:205-10. doi:10.1007/s10620-014-3316-y
116. Bashir A, Miskeen AY, Hazari YM, Asrafuzzaman S, Fazili KM. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol (2016) 37:2805-10. doi:10.1007/s13277-015-4724-0
117. Lidar M, Langevitz P, Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. Isr Med Assoc J (2009) 11:558-63
118. Chen W, Li D, Paulus B, Wilson I, Chadwick VS. Detection of Listeria monocytogenes by polymerase chain reaction in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol (2000) 15:1145-50. doi:10.1046/j.1440-1746.2000.02331.x
119. Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol (2009) 60:107-18
120. Zwolinska-Wcislo M, Budak A, Trojanowska D, Mach T, Rudnicka-Sosin L, Galicka-Latala D, et al. [The influence of Candida albicans on the course of ulcerative colitis]. Przegl Lek (2006) 63:533-8
121. Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol (2011) 8:135-45. doi:10.1038/cmi.2010.81
122. Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, Mortellaro A. The rhapsody of NLRPs: master players of inflammation.. and a lot more. Immunol Res (2012) 53:78-90. doi:10.1007/s12026-012-8272-z
123. Zhang Z, Shen P, Lu X, Li Y, Liu J, Liu B, et al. In vivo and in vitro study on the efficacy of terpinen-4-ol in dextran sulfate sodium-induced mice experimental colitis. Front Immunol (2017) 8:558. doi:10.3389/fimmu.2017.00558
124. Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity (2010) 32:367-78. doi:10.1016/j.immuni.2010.02.012
125. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis (2011) 17:1359-72. doi:10.1002/ibd.21478
126. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut (2010) 59:1192-9. doi:10.1136/gut.2009.197822
127. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med (2010) 207:1045-56. doi:10.1084/jem.20100050
128. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell (2011) 145:745-57. doi:10.1016/j.cell.2011.04.022
129. Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang JP, Brown EM, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell (2014) 156:1045-59. doi:10.1016/j.cell.2014.01.026
130. Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity (2012) 36:742-54. doi:10.1016/j.immuni.2012.03.012
131. Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 20:649-60. doi:10.1016/j.ccr.2011.10.022
132. Berridge MJ. Vitamin D and depression: cellular and regulatory mechanisms. Pharmacol Rev (2017) 69:80-92. doi:10.1124/pr.116.013227
133. Al Mheid I, Quyyumi AA. Vitamin D and cardiovascular disease controversy unresolved. J Am Coll Cardiol (2017) 70:89-100. doi:10.1016/j.jacc.2017.05.031
134. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer (2014) 14:342-57. doi:10.1038/nrc3691
135. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res (1998) 13:325-49. doi:10.1359/jbmr.1998.13.3.325
136. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J (2005) 19:1067-77. doi:10.1096/fj.04-3284com
137. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) (2010) 88:441-50. doi:10.1007/s00109-010-0590-9
138. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol (2008) 294:G208-16. doi:10.1152/ajpgi.00398.2007
139. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Ann N Y Acad Sci (2009) 1173:757-65. doi:10.1111/j.1749-6632.2009.04637.x
140. Wu S, Liao AP, Xia Y, Li YC, Li JD, Sartor RB, et al. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am J Pathol (2010) 177:686-97. doi:10.2353/ajpath.2010.090998
141. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut (2004) 53:1129-36. doi:10.1136/gut.2003.036657
142. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis (2006) 12:1162-74. doi:10.1097/01.mib.0000236929.74040.b0
143. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr (2002) 76:1077-81
144. Ooi JH, Li Y, Rogers CJ, Cantorna MT. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr (2013) 143:1679-86. doi:10.3945/jn.113.180794
145. Cantorna MT, McDaniel K, Bora S, Chen J, James J. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp Biol Med (Maywood) (2014) 239:1524-30. doi:10.1177/1535370214523890
146. Wang J, Thingholm LB, Skieceviciene J, Rausch P, Kummen M, Hov JR, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet (2016) 48:1396-406. doi:10.1038/ng.3695
147. Chen SW, Wang PY, Zhu J, Chen GW, Zhang JL, Chen ZY, et al. Protective effect of 1,25-dihydroxyvitamin d3 on lipopolysaccharide-induced intestinal epithelial tight junction injury in caco-2 cell monolayers. Inflammation (2015) 38:375-83. doi:10.1007/s10753-014-0041-9
148. Jahani R, Fielding KA, Chen J, Villa CR, Castelli LM, Ward WE, et al. Low vitamin D status throughout life results in an inflammatory prone status but does not alter bone mineral or strength in healthy 3-month-old CD-1 male mice. Mol Nutr Food Res (2014) 58:1491-501. doi:10.1002/mnfr.201300928
149. Jin D, Wu S, Zhang YG, Lu R, Xia Y, Dong H, et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Am J Physiol Gastrointest Liver Physiol (2015) 37:996-1009.e1007. doi:10.1152/ajpgi.00105.2015
150. Ryz NR, Patterson SJ, Zhang Y, Ma C, Huang T, Bhinder G, et al. Active vitamin D (1,25-dihydroxyvitamin D3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses. Am J Physiol Gastrointest Liver Physiol (2012) 303:G1299-311. doi:10.1152/ajpgi.00320.2012
151. Assa A, Vong L, Pinnell LJ, Rautava J, Avitzur N, Johnson-Henry KC, et al. Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injury. Inflamm Bowel Dis (2015) 21:297-306. doi:10.1097/mib.0000000000000282
152. Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A (2008) 105:20834-9. doi:10.1073/pnas.0808700106
153. Wu S, Yoon S, Zhang YG, Lu R, Xia Y, Wan J, et al. Vitamin D receptor pathway is required for probiotic protection in colitis. Am J Physiol Gastrointest Liver Physiol (2015) 309:G341-9. doi:10.1021/acs.jafc.5b05415
154. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol (2003) 36:22-5. doi:10.1097/00004836-200301000-00008
155. Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev (2009) 20:97-113. doi:10.1016/j.cytogfr.2009.02.004
156. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity (2014) 40:843-54. doi:10.1016/j.immuni.2014.05.013
157. Carvalho FA, Nalbantoglu I, Ortega-Fernandez S, Aitken JD, Su Y, Koren O, et al. Interleukin-1beta (IL-1beta) promotes susceptibility of toll-like receptor 5 (TLR5) deficient mice to colitis. Gut (2012) 61:373-84. doi:10.1136/gut.2011.240556
158. Demon D, Kuchmiy A, Fossoul A, Zhu Q, Kanneganti TD, LamkanfiM. Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol (2014) 7:1480-91. doi:10.1038/mi.2014.36
159. Yang JY, Kim MS, Kim E, Cheon JH, Lee YS, Kim Y, et al. Enteric viruses ameliorate gut inflammation via toll-like receptor 3 and toll-like receptor 7-mediated interferon-beta production. Immunity (2016) 44:889-900. doi:10.1016/j.immuni.2016.03.009
160. Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J (2004) 23:1998-2008. doi:10.1038/sj.emboj.7600202
161. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin (2016) 37:571-9. doi:10.1038/aps.2016.9
162. Jorgensen JR, Fransson A, Fjord-Larsen L, Thompson LH, Houchins JP, Andrade N, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol (2012) 233:172-81. doi:10.1016/j.expneurol.2011.09.027
163. Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. Subfatin is a novel adipokine and unlike meteorin in adipose and brain expression. CNS Neurosci Ther (2014) 20:344-54. doi:10.1111/cns.12219
164. Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte Metrnl antagonizes insulin resistance through PPAR gamma signaling. Diabetes (2015) 64:4011-22. doi:10.2337/db15-0274
165. Li ZY, Fan MB, Zhang SL, Qu Y, Zheng SL, Song J, et al. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol Sin (2016) 37:1458-66. doi:10.1038/aps.2016.70